Drug intelligence / Profile preview

EPRA-0322

Development stage: Preclinical
Lead developer: EPOK Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

EPRA-0322 is a mono-specific antibody engineered as a highly specific erythropoietin receptor (EPOR) agonist. It is designed for low-dose, infrequent subcutaneous administration (4–6 times per year), aiming to provide a more convenient and potentially safer alternative to traditional recombinant erythropoietin therapies. Unlike existing EPO-based treatments, EPRA-0322 is developed to avoid activation of non-target receptors, thereby reducing the risk of off-target effects. The drug is being advanced by EPOK Therapeutics for the management of anemia, particularly in patients with chronic kidney disease (CKD), cancer, or those undergoing chemotherapy or HIV treatment[1][2].

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on EPRA-0322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPRA-0322.

Explore the full profile